<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" id="ame212489" xml:lang="en" article-type="correction"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Animal Model Exp Med</journal-id><journal-id journal-id-type="iso-abbrev">Animal Model Exp Med</journal-id><journal-id journal-id-type="doi">10.1002/(ISSN)2576-2095</journal-id><journal-id journal-id-type="publisher-id">AME2</journal-id><journal-title-group><journal-title>Animal Models and Experimental Medicine</journal-title></journal-title-group><issn pub-type="ppub">2096-5451</issn><issn pub-type="epub">2576-2095</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39176989</article-id><article-id pub-id-type="pmc">PMC11680481</article-id><article-id pub-id-type="doi">10.1002/ame2.12489</article-id><article-id pub-id-type="publisher-id">AME212489</article-id><article-categories><subj-group subj-group-type="overline"><subject>Correction</subject></subj-group><subj-group subj-group-type="heading"><subject>Regular Article</subject><subj-group subj-group-type="heading"><subject>Correction</subject></subj-group></subj-group></article-categories><title-group><article-title>Correction to &#x0201c;Overexpression of <styled-content style="fixed-case" toggle="no">ACE2</styled-content> ameliorates A&#x003b2;&#x02010;induced blood&#x02013;brain barrier damage and angiogenesis by inhibiting <styled-content style="fixed-case" toggle="no">NF</styled-content>&#x02010;<styled-content style="fixed-case" toggle="no">&#x003ba;B</styled-content>/<styled-content style="fixed-case" toggle="no">VEGF</styled-content>/<styled-content style="fixed-case" toggle="no">VEGFR2</styled-content> pathway&#x0201d;</article-title></title-group><pub-date pub-type="epub"><day>23</day><month>8</month><year>2024</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2024</year></pub-date><pub-date pub-type="pmc-release"><day>23</day><month>8</month><year>2024</year></pub-date><!--PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>.--><volume>7</volume><issue seq="230">6</issue><issue-id pub-id-type="doi">10.1002/ame2.v7.6</issue-id><issue-title>Themed Issue: Bone Regeneration and Disease Mechanisms</issue-title><fpage>966</fpage><lpage>967</lpage><permissions><!--&#x000a9; 2024 The Chinese Association for Laboratory Animal Sciences.--><copyright-statement content-type="article-copyright">&#x000a9; 2024 The Author(s). <italic toggle="yes">Animal Models and Experimental Medicine</italic> published by John Wiley &#x00026; Sons Australia, Ltd on behalf of The Chinese Association for Laboratory Animal Sciences</copyright-statement><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="file:AME2-7-966.pdf"/><related-article related-article-type="corrected-article" ext-link-type="doi" id="RA1" xlink:href="10.1002/ame2.12324">10.1002/ame2.12324</related-article><counts><fig-count count="3"/><table-count count="0"/><page-count count="2"/><word-count count="300"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>December 2024</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.5.1 mode:remove_FC converted:28.12.2024</meta-value></custom-meta></custom-meta-group></article-meta></front><body id="ame212489-body-0001"><p>Xueling Zhang, Yu Zhang, Ling Zhang*, Chuan Qin*, <italic toggle="yes">Anim Models Exp Med</italic>. 2023;6:237&#x02013;244.</p><p>In Figure&#x000a0;<xref rid="ame212489-fig-0001" ref-type="fig">2A</xref>, the picture of immune blot for GAPDH was misplaced. The correct picture has been added to the updated Figure&#x000a0;<xref rid="ame212489-fig-0001" ref-type="fig">2A</xref>.</p><fig position="float" fig-type="FIGURE" id="ame212489-fig-0001"><label>FIGURE 2</label><caption><p>A&#x003b2;<sub>25&#x02010;35</sub> treatment downregulates ACE2 expression in bEnd.3 cell. (A) Western blot analysis showing the expression levels of ACE2. GAPDH levels were measured to confirm that equal amounts of protein were loaded. (B) Histogram quantifying the results shown in (A). The data are represented as means&#x02009;&#x000b1;&#x02009;SD for three replicates. *<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.05.</p></caption><graphic xlink:href="AME2-7-966-g003" position="anchor" id="jats-graphic-1"/></fig><p>In figure&#x000a0;<xref rid="ame212489-fig-0002" ref-type="fig">6A</xref>, the picture of immune blot for GAPDH was misplaced and the molecular weight of VEGFa was mistakenly marked. The correct picture has been added to the updated Figure&#x000a0;<xref rid="ame212489-fig-0002" ref-type="fig">6A</xref>.</p><fig position="float" fig-type="FIGURE" id="ame212489-fig-0002"><label>FIGURE 6</label><caption><p>ACE2 inhibits the activation of the VEGF pathway induced by A&#x003b2;<sub>25&#x02010;35</sub>. (A) Western blot analysis showing the expression levels of VEGFR2, p&#x02010;VEGFR2, and VEGFa. GAPDH levels were measured to confirm that equal amounts of protein were loaded. (B) Histogram quantifying the results for VEGFa shown in (A). (C) Histogram quantifying the results for the ratio of phosphorylated VEGFR2 shown in (A).</p></caption><graphic xlink:href="AME2-7-966-g002" position="anchor" id="jats-graphic-3"/></fig><p>In Figure&#x000a0;<xref rid="ame212489-fig-0003" ref-type="fig">8A</xref>, the picture of immune blot for GAPDH was misplaced. The correct picture has been added to the updated Figure&#x000a0;<xref rid="ame212489-fig-0003" ref-type="fig">8A</xref>.</p><fig position="float" fig-type="FIGURE" id="ame212489-fig-0003"><label>FIGURE 8</label><caption><p>ACE2 inhibits the activation of the NF&#x02010;&#x003ba;B pathway induced by A&#x003b2;<sub>25&#x02010;35</sub>. (A) Western blot analysis showing the expression levels of pNF&#x02010;&#x003ba;B and NF&#x02010;&#x003ba;B. GAPDH levels were measured to confirm that equal amounts of protein were loaded. (B) Histogram quantifying the results for the ratio of phosphorylated NF&#x02010;&#x003ba;B shown in (A). *<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.05.</p></caption><graphic xlink:href="AME2-7-966-g001" position="anchor" id="jats-graphic-5"/></fig><p>We apologize for these errors.</p></body></article>